44mon MSN
Castle Biosciences outlines $33B AdvanceAD-Tx market opportunity while raising 2025 revenue guidance
Q3 2025 Management View Derek Maetzold, Founder, CEO, President & Director, announced the launch of AdvanceAD-Tx, a test designed to guide systemic treatment selection for patients with moderate to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback